Literature DB >> 18951468

BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).

Stefan Gattenlohner1, Hans-Ulrich Völker, Benjamin Etschmann, Hermann Einsele, Hans-Konrad Müller-Hermelink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 18951468     DOI： 10.1002/ajh.21296

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

2.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

4.  A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Authors:  Ping Chong Bee; G G Gan; V S Nadarajan; N A Latiff; N Menaka
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

5.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

6.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.